[{"Assets_0_Q2_USD":389922000.0,"CommonStockSharesOutstanding_0_Q2_shares":331307810.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-22180000.0,"NetIncomeLoss_1_Q2_USD":-1820000.0,"NetIncomeLoss_2_Q2_USD":-26251000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":330863000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":329793000.0,"StockholdersEquity_0_Q2_USD":149087000.0,"EarningsPerShareBasic_1_Q2_USD":-0.01,"EarningsPerShareBasic_2_Q2_USD":-0.08,"Ticker":"AMRN","CIK":"897448","name":"AMARIN CORP PLCUK","OfficialName":"Amarin Corporation plc","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1265593617.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20190731"}]